GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Terence J. Purdon et al.|New England Journal of Medicine|2022Cited by 383
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Malin Hultcrantz et al.|JAMA Oncology|2021Cited by 119
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination SurveyOla Landgren, S. Vincent Rajkumar, Barry I. Graubard et al.|Blood Cancer Journal|2017Cited by 116
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Ingemar Turesson, Jonathan N. Hofmann et al.|JAMA Oncology|2019Cited by 97